How High Hematocrit Is Dangerous: Thresholds and Effects

Hematocrit levels above roughly 49% in men and 48% in women enter the range doctors consider elevated, and the danger rises steeply as the number climbs past the mid-forties into the fifties and beyond. The core problem is straightforward: more red blood cells make blood thicker, and thicker blood is harder to push through vessels, more prone to clotting, and worse at delivering oxygen to the tissues that need it most. But the picture is more nuanced than a single cutoff number, because the risks depend on how quickly hematocrit rose, what caused it, and what other cardiovascular risk factors a person carries.

Why Thicker Blood Causes Harm

Hematocrit measures the percentage of your blood volume occupied by red blood cells. A higher percentage means a more packed, viscous fluid flowing through your vessels. Blood viscosity is influenced by both the concentration of red cells and the properties of plasma, and any increase in viscosity raises the resistance your heart has to pump against. Under normal conditions, the shear force of flowing blood against vessel walls stimulates the lining cells to produce nitric oxide, a molecule that keeps vessels relaxed and open. When blood gets too thick, that balance shifts: flow slows in smaller vessels, shear patterns change, and the chemical signals that maintain healthy vessel tone get disrupted.¹

At the same time, sluggish flow gives platelets more time in contact with vessel walls, making clot formation more likely. Red blood cells themselves contribute by releasing a chemical called ADP when they are activated, which further ramps up platelet stickiness. The result is a self-reinforcing cycle: thicker blood flows more slowly, and slower flow promotes the very clotting events that make high hematocrit dangerous.²

Where the Danger Thresholds Fall

Clinically, erythrocytosis is defined as hemoglobin above 16.5 g/dL or hematocrit above 49% in men, and hemoglobin above 16.0 g/dL or hematocrit above 48% in women.³ Those numbers flag a patient as worth investigating, but they do not mark an instant tipping point. Risk for complications like stroke appears to climb once hematocrit passes about 45%, and it rises proportionally above that level.⁴ One older but frequently cited study found that the incidence of cerebral infarction was higher in patients with hematocrit above 46%, and the increase was especially pronounced in people who already had significant narrowing of brain arteries.⁵

For treatment purposes, the widely used clinical target is to keep hematocrit below 45%. That number comes from evidence that thrombotic events in conditions like polycythemia vera drop meaningfully once hematocrit stays under that ceiling.⁶ To put the extreme end in perspective, a case report documented a patient with a hematocrit of 62.5% who suffered an ischemic stroke; his neurological deficits improved markedly within four days of therapeutic phlebotomy that brought his hematocrit down to about 49%.⁴

Stroke and Heart Risk

The brain is one of the most vulnerable organs when hematocrit rises. Elevated hematocrit reduces cerebral blood flow by increasing viscosity and peripheral resistance, while simultaneously ramping up platelet activation and oxidative stress.² Ischemic strokes in the deep subcortical structures of the brain appear to be more strongly associated with high hematocrit than cortical strokes, likely because the small penetrating arteries supplying those deep regions are especially sensitive to changes in blood flow and viscosity.⁵

The cardiovascular picture extends beyond stroke. Research in shock patients has shown partial associations between hematocrit and heart rate, with heart rate tending to increase as hematocrit rises, and mean arterial pressure tending to rise as hematocrit falls.⁷ This fits with the broader understanding that the heart has to work harder to push thicker blood, which over time can strain the cardiovascular system. The risk is not limited to one type of blood vessel event either: both arterial clots (heart attacks, strokes) and venous clots (deep vein thrombosis, pulmonary embolism) become more likely.

What Pushes Hematocrit Too High

The causes of elevated hematocrit split into two broad camps. The first is a true increase in red blood cell mass, called absolute erythrocytosis. This can be primary, meaning the bone marrow itself is overproducing red cells due to a genetic mutation (as in polycythemia vera), or secondary, meaning the body is making more red cells in response to some outside signal like chronic low oxygen levels, kidney tumors that produce erythropoietin, or testosterone therapy.³

The second camp is relative erythrocytosis, where the red cell count is normal but the plasma volume has shrunk, making the same number of cells appear more concentrated. Dehydration is the classic cause. This distinction matters for treatment: someone who is dehydrated after a stomach bug needs fluids, not a hematology workup, whereas someone whose bone marrow is churning out extra red cells may need ongoing medical management.

An important and somewhat counterintuitive finding is that secondary erythrocytosis may carry a higher clot risk than polycythemia vera itself. A real-world study comparing the two conditions found that secondary erythrocytosis was associated with a combined thrombosis rate of about 2.7 events per 100 patient-years, compared with roughly 1.4 per 100 patient-years in polycythemia vera. Secondary erythrocytosis carried about three times the thrombosis risk after adjusting for other factors.⁸ This is probably because patients with polycythemia vera tend to get closer monitoring and more aggressive treatment, while secondary erythrocytosis often goes underappreciated. It also reflects the fact that patients with secondary erythrocytosis frequently have underlying conditions like chronic lung disease or heart failure that independently raise clot risk.

Testosterone Therapy and Hematocrit

One of the fastest-growing causes of elevated hematocrit is testosterone replacement therapy (TRT). Testosterone stimulates erythropoietin production, which tells the bone marrow to make more red blood cells. For many men, this bump is modest. But in a meaningful fraction, hematocrit climbs into the polycythemia range. A large study defined polycythemia as hematocrit at or above 52% and found that men who developed polycythemia while on testosterone had a higher rate of major adverse cardiovascular events and venous thromboembolism compared to men whose hematocrit stayed normal: about 5.2% vs. 3.9% experienced an event in the first year of therapy, with an odds ratio of roughly 1.35.⁹

This means developing polycythemia on testosterone is an independent risk factor for cardiovascular trouble, not just a lab abnormality to be noted and ignored. Most prescribing guidelines now recommend checking hematocrit before starting testosterone and monitoring it periodically afterward, with dose reduction or temporary discontinuation if the number rises too high. The 52% threshold used in that study is stricter than the general erythrocytosis definition of 49%, which reflects the clinical concern that even levels in the high-normal range may carry extra risk in the context of ongoing testosterone exposure.

Bringing Hematocrit Back Down

The oldest and most direct treatment for dangerously high hematocrit is phlebotomy, the controlled removal of blood. In polycythemia vera, phlebotomy targets a hematocrit below 45% to prevent thrombotic events. Research on timing suggests that phlebotomies spaced less than two weeks apart are most effective for driving hematocrit down initially, while intervals of up to four weeks can maintain the target once it has been reached.⁶ Phlebotomy is safe and effective regardless of whether the patient is also taking medication.

For patients with polycythemia vera who need more than phlebotomy, several drugs can help. Ruxolitinib, a targeted therapy, achieved hematocrit control in about 60% of patients in a landmark trial, compared with 20% on standard therapy. That same trial also found that clotting events occurred in only one patient on ruxolitinib versus six on standard treatment.¹⁰ In real-world follow-up, roughly 88-89% of patients achieved hematocrit control within three to six months of starting ruxolitinib, with very few thrombotic events observed.¹¹

A newer option, ropeginterferon alfa-2b, has also been studied. A meta-analysis of three randomized trials found that while it did not clearly outperform hydroxyurea overall, it showed significant benefits over phlebotomy alone for achieving complete hematological response and reducing the disease’s genetic burden.¹² The treatment landscape is expanding, which matters because polycythemia vera is a lifelong condition that requires sustained management.

Blood Doping and Athletes

Everything that makes high hematocrit dangerous for patients also applies to athletes who artificially boost their red cell mass. Injecting erythropoietin (EPO) or transfusing stored blood raises hematocrit to carry more oxygen, which improves endurance performance. But the cardiovascular and clotting risks come along for the ride. EPO not only increases red cell volume but also shrinks plasma volume even before new red cells appear, compounding the viscosity problem during the very endurance activities where athletes are already losing fluid through sweat.¹³

The deaths of 18 Dutch and Belgian cyclists between 1987 and 1990, during a period when EPO use was spreading through professional cycling, have never been fully explained. Hyperviscosity from blood boosting is the leading suspected cause.¹³ The irony is that pushing hematocrit too high can actually reverse the performance benefit: extremely thick blood reduces peripheral blood flow and increases the heart’s workload to the point where aerobic power deteriorates rather than improves. Sports governing bodies introduced hematocrit testing partly to protect athlete health by preventing competition when levels were dangerously elevated.¹⁴ EPO use carries documented risks of hypertension, heart attack, and stroke even outside the context of athletic exertion.¹⁵

Newborns Play by Different Rules

Normal hematocrit in a newborn is substantially higher than in an adult, so the thresholds for concern are completely different. Neonatal polycythemia is defined as a hematocrit at or above 65%, a number that would be a medical emergency in an adult but is seen in a small percentage of otherwise healthy newborns. Hyperviscosity in neonates can alter blood flow to certain organs and cause symptoms like jitteriness, poor feeding, or bluish skin.¹⁶

The treatment for severe cases is partial exchange transfusion, where some of the baby’s thick blood is removed and replaced with saline or albumin. However, the evidence for this intervention is surprisingly thin. Studies of long-term brain development have not shown clear benefits from treatment in babies who are asymptomatic, meaning the high hematocrit was caught on a routine blood test but the baby seemed fine.¹⁶ For babies who are showing symptoms, treatment is generally offered, but even there the long-term data are not conclusive. This is one of those areas in medicine where the decision about whether to treat depends more on clinical judgment than on strong trial evidence.

When a High Reading Is Not Real

Before anyone gets alarmed by a single high hematocrit result, it is worth knowing that lab errors can produce falsely elevated readings. The most common source of preanalytical errors involves problems with how the blood sample was collected, handled, or transported.¹⁷ Overfilling a blood collection tube, for example, can result in inadequate mixing of the blood with the anticoagulant inside the tube, and that can produce a falsely high hematocrit reading, sometimes called pseudo polycythemia.¹⁸

A less obvious artifact involves blood sugar. In patients with severe hyperglycemia, the highly concentrated glucose in the blood causes red blood cells to swell osmotically when mixed with the diluting fluid used in automated blood counters. This swelling inflates the measured cell volume and, because hematocrit is calculated from cell volume, produces a spuriously high hematocrit. When the patient’s blood sugar normalizes, the hematocrit drops to its true value without any change in the actual number of red cells.¹⁹ This is a good reason to repeat an unexpectedly high hematocrit result before pursuing a major workup, especially if the patient was dehydrated or had uncontrolled diabetes at the time of the blood draw.

A Paradox With Diabetes Drugs

An interesting wrinkle in the relationship between hematocrit and cardiovascular risk comes from a class of diabetes medications called SGLT2 inhibitors, which includes drugs like dapagliflozin. These drugs cause the kidneys to excrete more glucose and water, which concentrates the blood and raises hematocrit modestly. Ordinarily, you would expect that hematocrit bump to worsen blood flow through small vessels and increase clotting risk. But a randomized controlled trial specifically designed to test this found the opposite: 16 weeks of dapagliflozin therapy did not adversely affect blood flow properties at the small-vessel level, even though hematocrit and erythropoietin levels both rose. The study demonstrated that the hematocrit elevation from dapagliflozin was not associated with worsened microvascular blood fluidity, increased white blood cell stickiness, or higher oxidative stress.²⁰

This matters because SGLT2 inhibitors have shown striking cardiovascular and kidney protection in large trials, and the mild hematocrit increase they cause has been proposed as one of the mechanisms through which they help, possibly by improving oxygen delivery to tissues. It is a reminder that the dose makes the poison: a modest hematocrit rise driven by a specific mechanism can behave very differently from the dangerous hyperviscosity seen in polycythemia or blood doping. Not all hematocrit elevations are equally threatening, and the context in which the number rises can completely change its clinical significance.

High-Altitude Adaptation Across Species

Hematocrit rises naturally at high altitude in humans and many other animals as the body compensates for lower oxygen availability. Research on black-spotted frogs at different elevations found that high-altitude populations had significantly increased hematocrit and hemoglobin concentration, but also had smaller individual red blood cells. Smaller cells have a higher surface-area-to-volume ratio, which makes them more efficient at loading and unloading oxygen.²¹ In humans, similar compensatory changes occur when people move to high altitude, though the process takes weeks to months to fully develop.

For people living at high altitude permanently, a moderately elevated hematocrit is normal physiology, not pathology. Problems arise when the adaptation overshoots. Chronic mountain sickness, sometimes called Monge’s disease, is a condition where long-term high-altitude residents develop excessively high hematocrit with symptoms like headache, fatigue, confusion, and elevated clotting risk. The line between healthy altitude adaptation and a disease state is another demonstration that hematocrit thresholds are not absolute numbers but depend on the person’s environment and baseline physiology. A hematocrit of 52% in someone living in Denver warrants a different reaction than the same number in someone living at sea level.